Radiosensitizing nucleosides.
Chemotherapeutic drugs that perturb nucleotide metabolism have the potential to produce substantial sensitization of tumor cells to radiation treatment. The process is called radiosensitization, and the agents that induce it are called radiosensitizers. The clinical effectiveness of fluoropyrimidines as radiosensitizers has been proven in multiple randomized trials. Thymidine analogues and hydroxyurea also appear to produce clinically relevant increases in radiation sensitivity. Recent laboratory investigations have identified difluorodeoxycytidine (gemcitabine) and fludarabine as promising agents to use in combination with radiation. Until recently, little was known about how the biochemical changes caused by these drugs produced radiosensitization. However, advances in related fields, such as cell cycle checkpoint control, have permitted the development of a hypothesis that may explain the relative tumor selectivity of fluoropyrimidine-mediated radiosensitization. In addition, recent findings suggest that the rational manipulation of drug administration schedules and the use of combinations of radiosensitizers have the potential to improve the efficacy of the currently used agents and to establish the benefit of new ones.
McGinn
C J
CJ
Department of Radiation Oncology, University of Michigan, Ann Arbor 48109-0582, USA.
Shewach
D S
DS
Lawrence
T S
TS
D000818:Animals; D003841:Deoxycytidine / Q000031:analogs & derivatives; D006801:Humans; D006918:Hydroxyurea; D009705:Nucleosides; D011743:Pyrimidines; D011838:Radiation-Sensitizing Agents; D013936:Thymidine / Q000031:analogs & derivatives; D014740:Vidarabine / Q000031:analogs & derivatives; D000093542:Gemcitabine
D009705:Nucleosides; D011743:Pyrimidines; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; C029269:5-fluoropyrimidine; D014740:Vidarabine; C024352:fludarabine; D013936:Thymidine; D006918:Hydroxyurea; D000093542:Gemcitabine